{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:20:03Z","timestamp":1768530003793,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-025-01395-6","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:04:33Z","timestamp":1768194273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changing Perspectives in Managing Metastatic Gallbladder Cancer: Defining Oligometastatic Disease, Current Treatments, and Emerging Therapies"],"prefix":"10.1007","volume":"57","author":[{"given":"Kailash Chand","family":"Kurdia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spiros","family":"Delis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chethan","family":"R.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"SheinMyint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay K.","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"issue":"10272","key":"1395_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(21)00153-7.","journal-title":"Lancet"},{"issue":"3","key":"1395_CR2","doi-asserted-by":"publisher","DOI":"10.21037\/cco-20-230","volume":"10","author":"M Alkhayyat","year":"2021","unstructured":"Alkhayyat M, Abou Saleh M, Qapaja T, Abureesh M, Almomani A, Mansoor E, et al. Epidemiology of gallbladder cancer in the Unites States: a population-based study. Chin Clin Oncol. 2021;10(3):25. https:\/\/doi.org\/10.21037\/cco-20-230.","journal-title":"Chin Clin Oncol"},{"issue":"1","key":"1395_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00398-y","volume":"8","author":"JC Roa","year":"2022","unstructured":"Roa JC, Garc\u00eda P, Kapoor VK, Maithel SK, Javle M, Koshiol J. Gallbladder cancer. Nat Rev Dis Primers. 2022;8(1):69. https:\/\/doi.org\/10.1038\/s41572-022-00398-y.","journal-title":"Nat Rev Dis Primers"},{"issue":"14","key":"1395_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721.","journal-title":"N Engl J Med"},{"key":"1395_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejca.2019.10.004","volume":"123","author":"A Sharma","year":"2019","unstructured":"Sharma A, KalyanMohanti B, Pal Chaudhary S, Sreenivas V, Kumar Sahoo R, Kumar Shukla N, Thulkar S, Pal S, Deo SV, Pathy S, Ranjan Dash N, Kumar S, Bhatnagar S, Kumar R, Mishra S, Sahni P, Iyer VK, Raina V. Modified gemcitabine and oxaliplatin or gemcitabine\u2009+\u2009cisplatin in unresectable gallbladder cancer: results of a phase III randomised controlled trial. Eur J Cancer. 2019;123:162\u201370. https:\/\/doi.org\/10.1016\/j.ejca.2019.10.004.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1395_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8\u201310. https:\/\/doi.org\/10.1200\/JCO.1995.13.1.8.","journal-title":"J Clin Oncol"},{"key":"1395_CR7","unstructured":"National Cancer Institute. Definition of oligometastasis. Availableat:https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/oligometastasis"},{"key":"1395_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","volume":"148","author":"Y Lievens","year":"2020","unstructured":"Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157\u201366. https:\/\/doi.org\/10.1016\/j.radonc.2020.04.003.","journal-title":"Radiother Oncol"},{"key":"1395_CR9","doi-asserted-by":"crossref","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z et al. KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u20131865. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4. Erratum in: Lancet. 2023;402(10406):964. https:\/\/doi.org\/10.1016\/S0140-6736(23)01904-9. Erratum in: Lancet. 2024;403(10432):1140. https:\/\/doi.org\/10.1016\/S0140-6736(24)00545-2.","DOI":"10.1016\/S0140-6736(24)00545-2"},{"issue":"8","key":"1395_CR10","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. The Lancet Gastroenterology & Hepatology. 2024;9(8):694\u2013704. https:\/\/doi.org\/10.1016\/S2468-1253(24)00095-5.","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"Suppl 3","key":"1395_CR11","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1245\/s10434-021-10327-0","volume":"28","author":"K Morino","year":"2021","unstructured":"Morino K, Seo S, Yoh T, Fukumitsu K, Ishii T, Taura K, Morita S, Kaido T, Uemoto S. Correction to: Proposed definition for oligometastatic recurrence in biliary tract cancer based on results of locoregional treatment: A Propensity-Score-Stratified analysis. Ann SurgOncol. 2021;28(Suppl 3):884. https:\/\/doi.org\/10.1245\/s10434-021-10327-0. Erratum for: Ann SurgOncol. 2020;27(6):1908\u20131917. doi: 10.1245\/s10434-020-08207-0.","journal-title":"Ann SurgOncol"},{"issue":"4","key":"1395_CR12","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1007\/s12029-024-01098-4","volume":"55","author":"T Okamoto","year":"2024","unstructured":"Okamoto T, Takeda T, Sasaki T, Inoue Y, Mie T, Hirai T, et al. Liver oligometastasis in biliary tract cancer and impact on survival outcomes. J Gastrointest Cancer. 2024;55(4):1530\u201340. https:\/\/doi.org\/10.1007\/s12029-024-01098-4.","journal-title":"J Gastrointest Cancer"},{"issue":"1","key":"1395_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12876-022-02234-9","volume":"22","author":"R Higuchi","year":"2022","unstructured":"Higuchi R, Ono H, Matsuyama R, Takemura Y, Kobayashi S, Otsubo T, Abe Y, Endo I, Tanabe M, Yamamoto M, Association for Clinical Research on Surgery Group (ACRoS1406. Examination of the characteristics of long-term survivors among patients with gallbladder cancer with liver metastasis who underwent surgical treatment: a retrospective multicenter study (ACRoS1406). BMC Gastroenterol. 2022;22(1):152. https:\/\/doi.org\/10.1186\/s12876-022-02234-9.","journal-title":"BMC Gastroenterol"},{"key":"1395_CR14","doi-asserted-by":"publisher","first-page":"S485","DOI":"10.1016\/j.hpb.2022.05.1043","volume":"24","author":"S Patel","year":"2022","unstructured":"Patel S, Patkar S, Goel M. Extended indications of curative surgery in oligometastatic gallbladder cancers: survival benefit. HPB. 2022;24:S485\u20136.","journal-title":"HPB"},{"issue":"2","key":"1395_CR15","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.ejso.2022.11.593","volume":"49","author":"A Kunte","year":"2023","unstructured":"Kunte A, Goel M, Patkar S, Chaudhari V, Patel S. Surgical resection in oligo-metastatic gallbladder cancer: study protocol for a phase II randomized clinical trial. Eur J Surg Oncol. 2023;49(2):e54.","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"1395_CR16","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.suc.2024.03.006","volume":"104","author":"GC Waller","year":"2024","unstructured":"Waller GC, Sarpel U. Gallbladder Cancer. Surg Clin North Am. 2024;104(6):1263\u201380. https:\/\/doi.org\/10.1016\/j.suc.2024.03.006.","journal-title":"Surg Clin North Am"},{"key":"1395_CR17","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/GO.20.00657","volume":"7","author":"A Sharma","year":"2021","unstructured":"Sharma A, Pramanik R, Kumar A, Pathy S, Kumar S, Bhoriwal S, et al. Safety and efficacy of modified FOLFIRINOX in unresectable or metastatic gallbladder cancer: a phase II pilot study. JCO Glob Oncol. 2021;7:820\u20136. https:\/\/doi.org\/10.1200\/GO.20.00657.","journal-title":"JCO Glob Oncol"},{"issue":"4","key":"1395_CR18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.21037\/hbsn-20-846","volume":"10","author":"XY Cui","year":"2021","unstructured":"Cui XY, Li XC, Cui JJ, Wu XS, Zou L, Song XL, et al. Modified FOLFIRINOX for unresectable locally advanced or metastatic gallbladder cancer, a comparison with GEMOX regimen. Hepatobiliary Surg Nutr. 2021;10(4):498\u2013506. https:\/\/doi.org\/10.21037\/hbsn-20-846.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"1395_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/10732748231211764","volume":"30","author":"V Nghiem","year":"2023","unstructured":"Nghiem V, Wood S, Ramachandran R, Williams G, Outlaw D, Paluri R, et al. Short- and long-term survival of metastatic biliary tract cancer in the United States from 2000 to 2018. Cancer Control. 2023;30:10732748231211764. https:\/\/doi.org\/10.1177\/10732748231211764.","journal-title":"Cancer Control"},{"issue":"1","key":"1395_CR20","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2019.12.11","volume":"9","author":"P Iyer","year":"2020","unstructured":"Iyer P, Chen MH, Goyal L, Denlinger CS. Targets for therapy in biliary tract cancers: the new horizon of personalized medicine. Chin Clin Oncol. 2020;9(1):7. https:\/\/doi.org\/10.21037\/cco.2019.12.11.","journal-title":"Chin Clin Oncol"},{"issue":"1","key":"1395_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12893-021-01068-8","volume":"21","author":"Y Yang","year":"2021","unstructured":"Yang Y, Tu Z, Ye C, Cai H, Yang S, Chen X, et al. Site-specific metastases of gallbladder adenocarcinoma and their prognostic value for survival: a SEER-based study. BMC Surg. 2021;21(1):59. https:\/\/doi.org\/10.1186\/s12893-021-01068-8.","journal-title":"BMC Surg"},{"key":"1395_CR22","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.934447","volume":"28","author":"J Xie","year":"2022","unstructured":"Xie J, Liao Z, Sun C, Chen Z. Impact of primary tumor resection on survival of patients with metastatic gallbladder carcinoma: a population-based, propensity-matched study. Med Sci Monit. 2022;28:e934447. https:\/\/doi.org\/10.12659\/MSM.934447.","journal-title":"Med Sci Monit"},{"issue":"2","key":"1395_CR23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/SLA.0b013e318271497e","volume":"258","author":"AK Agarwal","year":"2013","unstructured":"Agarwal AK, Kalayarasan R, Javed A, Gupta N, Nag HH. The role of staging laparoscopy in primary gall bladder cancer\u2013an analysis of 409 patients: a prospective study to evaluate the role of staging laparoscopy in the management of gallbladder cancer. Ann Surg. 2013;258(2):318\u201323. https:\/\/doi.org\/10.1097\/SLA.0b013e318271497e.","journal-title":"Ann Surg"},{"issue":"8","key":"1395_CR24","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/cncr.11699","volume":"98","author":"WR Jarnagin","year":"2003","unstructured":"Jarnagin WR, Ruo L, Little SA, Klimstra D, D\u2019Angelica M, DeMatteo RP, Wagman R, Blumgart LH, Fong Y. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98(8):1689\u2013700. https:\/\/doi.org\/10.1002\/cncr.11699.","journal-title":"Cancer"},{"key":"1395_CR25","unstructured":"National Comprehensive Cancer Network. Biliary Tract Cancers (Version 3.2023). 2023. Available at:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/btc.pdf"},{"issue":"3","key":"1395_CR26","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00268-002-6654-4","volume":"27","author":"S Kondo","year":"2003","unstructured":"Kondo S, Nimura Y, Kamiya J, Nagino M, Kanai M, Uesaka K, Yuasa N, Sano T, Hayakawa N. Factors influencing postoperative hospital mortality and long-term survival after radical resection for stage IV gallbladder carcinoma. World J Surg. 2003;27(3):272\u20137. https:\/\/doi.org\/10.1007\/s00268-002-6654-4.","journal-title":"World J Surg"},{"issue":"3","key":"1395_CR27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.cdtm.2019.08.004","volume":"5","author":"C Chen","year":"2019","unstructured":"Chen C, Wang L, Zhang R, Li Q, Zhao YL, Zhang GJ, Li WZ, Geng ZM. Who benefits from R0 resection? A single-center analysis of patients with stage \u2163gallbladder cancer. Chronic Dis Transl Med. 2019;5(3):188\u201396. https:\/\/doi.org\/10.1016\/j.cdtm.2019.08.004.","journal-title":"Chronic Dis Transl Med"},{"issue":"12","key":"1395_CR28","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/j.1477-2574.2012.00544.x","volume":"14","author":"MJ Kang","year":"2012","unstructured":"Kang MJ, Song Y, Jang JY, Han IW, Kim SW. Role of radical surgery in patients with stage IV gallbladder cancer. HPB (Oxford). 2012;14(12):805\u201311. https:\/\/doi.org\/10.1111\/j.1477-2574.2012.00544.x.","journal-title":"HPB (Oxford)"},{"issue":"3","key":"1395_CR29","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00423-020-02068-7","volume":"406","author":"K Yuza","year":"2021","unstructured":"Yuza K, Sakata J, Hirose Y, Miura K, Ando T, Katada T, et al. Outcome of radical surgery for gallbladder carcinoma according to TNM stage: implications for adjuvant therapeutic strategies. Langenbecks Arch Surg. 2021;406(3):801\u201311. https:\/\/doi.org\/10.1007\/s00423-020-02068-7.","journal-title":"Langenbecks Arch Surg"},{"issue":"12","key":"1395_CR30","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1016\/j.ejso.2022.06.029","volume":"48","author":"AS Casabianca","year":"2022","unstructured":"Casabianca AS, Tsagkalidis V, Burchard PR, Chacon A, Melucci A, Reitz A, et al. Surgery in combination with systemic chemotherapy is associated with improved survival in stage IV gallbladder cancer. Eur J Surg Oncol. 2022;48(12):2448\u201354. https:\/\/doi.org\/10.1016\/j.ejso.2022.06.029.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"1395_CR31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.14701\/ahbps.22-111","volume":"27","author":"S Patkar","year":"2023","unstructured":"Patkar S, Patel S, Kazi M, Goel M. Radical surgery for stage IV gallbladder cancers: treatment strategies in patients with limited metastatic burden. Ann Hepatobiliary Pancreat Surg. 2023;27(2):180\u20138. https:\/\/doi.org\/10.14701\/ahbps.22-111.","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"issue":"4","key":"1395_CR32","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1177\/00031348211038563","volume":"89","author":"J Zhu","year":"2023","unstructured":"Zhu J, Hu W, Zhang Y, Du P, Xiao W, Li Y. Comparison of survival outcomes of chemotherapy plus surgery vs chemotherapy alone for patients with isolated liver metastases from gallbladder carcinoma. Am Surg. 2023;89(4):676\u201384. https:\/\/doi.org\/10.1177\/00031348211038563.","journal-title":"Am Surg"},{"issue":"1","key":"1395_CR33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12029-025-01294-w","volume":"56","author":"KC Kurdia","year":"2025","unstructured":"Kurdia KC, Kapoor VK. Gallbladder cancer and peritoneal metastasis: is there any role of cytoreductive surgery (CRS) and\/or hyperthermic intraperitoneal chemotherapy (HIPEC)? A narrative review. J Gastrointest Cancer. 2025;56(1):169. https:\/\/doi.org\/10.1007\/s12029-025-01294-w.","journal-title":"J Gastrointest Cancer"},{"issue":"1","key":"1395_CR34","doi-asserted-by":"publisher","first-page":"330","DOI":"10.21037\/jgo-23-816","volume":"15","author":"W Zhao","year":"2024","unstructured":"Zhao W, Yao Z, Li J, Li W, Dou Q, Zhao X, et al. Hepatic arterial infusion chemotherapy combined with bevacizumab plus a PD-1 inhibitor for gallbladder cancer with hepatic oligometastasis: a real-world study. J Gastrointest Oncol. 2024;15(1):330\u201345. https:\/\/doi.org\/10.21037\/jgo-23-816.","journal-title":"J Gastrointest Oncol"},{"issue":"9","key":"1395_CR35","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s00432-020-03285-9","volume":"146","author":"C Franzese","year":"2020","unstructured":"Franzese C, Bonu ML, Comito T, Clerici E, Loi M, Navarria P, Franceschini D, Pressiani T, Rimassa L, Scorsetti M. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. J Cancer Res Clin Oncol. 2020;146(9):2289\u201397. https:\/\/doi.org\/10.1007\/s00432-020-03285-9.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01395-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01395-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01395-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:25:28Z","timestamp":1768472728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01395-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1395"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01395-6","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"29 December 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}